Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ.

Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15735-40. Epub 2007 Sep 26.

2.

CXCR7 impact on CXCL12 biology and disease.

Sánchez-Martín L, Sánchez-Mateos P, Cabañas C.

Trends Mol Med. 2013 Jan;19(1):12-22. doi: 10.1016/j.molmed.2012.10.004. Epub 2012 Nov 12. Review.

PMID:
23153575
3.

CXCR7, CXCR4 and CXCL12: an eccentric trio?

Thelen M, Thelen S.

J Neuroimmunol. 2008 Jul 31;198(1-2):9-13. doi: 10.1016/j.jneuroim.2008.04.020. Epub 2008 Jun 3. Review.

PMID:
18533280
4.

CXCR7 in tumorigenesis and progression.

Hou KL, Hao MG, Bo JJ, Wang JH.

Chin J Cancer. 2010 Apr;29(4):456-9. Review.

5.

The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.

Shakir M, Tang D, Zeh HJ, Tang SW, Anderson CJ, Bahary N, Lotze MT.

Pancreas. 2015 May;44(4):528-34. doi: 10.1097/MPA.0000000000000298. Review.

PMID:
25872129
6.

[Recent advances and applications of CXCR7].

Shen Q, Wang F.

Zhonghua Bing Li Xue Za Zhi. 2009 May;38(5):358-60. Review. Chinese. No abstract available.

PMID:
19575889
7.

The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review).

Liao YX, Zhou CH, Zeng H, Zuo DQ, Wang ZY, Yin F, Hua YQ, Cai ZD.

Int J Mol Med. 2013 Dec;32(6):1239-46. doi: 10.3892/ijmm.2013.1521. Epub 2013 Oct 11. Review.

PMID:
24127013

Supplemental Content

Support Center